LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Search

Viatris Inc

Cerrado

SectorSalud

10.44 0.48

Resumen

Variación precio

24h

Actual

Mínimo

10.32

Máximo

10.5

Métricas clave

By Trading Economics

Ingresos

3B

-4.6M

Ventas

328M

3.6B

Rentabilidad por dividendo

4.61

Margen de beneficio

-0.128

Empleados

32,000

EBITDA

2.9B

578M

Recomendaciones

By TipRanks

Recomendaciones

Vender

Estimación a 12 meses

-14.29% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.61%

3.13%

Próximas Ganancias

6 nov 2025

Fecha Próximo Dividendo

15 sept 2025

Próxima Fecha de Ex Dividendo

21 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.8B

12B

Apertura anterior

9.96

Cierre anterior

10.44

Noticias sobre sentimiento de mercado

By Acuity

17%

83%

29 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Viatris Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2025, 23:59 UTC

Adquisiciones, fusiones, absorciones

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept 2025, 22:02 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Tron Shares Rise After New Investment From Bravemorning

8 sept 2025, 16:14 UTC

Principales Movimientos del Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept 2025, 16:13 UTC

Principales Movimientos del Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept 2025, 22:56 UTC

Charlas de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept 2025, 22:23 UTC

Charlas de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept 2025, 21:51 UTC

Charlas de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept 2025, 21:47 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 sept 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept 2025, 21:19 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 19:33 UTC

Charlas de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept 2025, 19:22 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept 2025, 19:02 UTC

Charlas de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept 2025, 17:29 UTC

Charlas de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept 2025, 16:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept 2025, 16:36 UTC

Charlas de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 16:16 UTC

Ganancias

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 sept 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Viatris Inc Esperado

Precio Objetivo

By TipRanks

-14.29% caída

Estimación a 12 meses

Media 9 USD  -14.29%

Máximo 10 USD

Mínimo 8 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Viatris Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

3 ratings

0

Comprar

2

Mantener

1

Vender

Puntuación técnica

By Trading Central

8.48 / N/ASoporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

29 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat